Participation in a Heart Failure Clinical Trial Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry

被引:13
作者
Ezekowitz, Justin [1 ]
Mentz, Robert J. [2 ]
Westerhout, Cynthia M. [1 ]
Sweitzer, Nancy K. [4 ]
Givertz, Michael M. [5 ]
Pina, Ileana L. [6 ]
O'Connor, Christopher M. [2 ,7 ]
Greene, Stephen J. [2 ,3 ]
McMullan, Ciaran [8 ]
Roessig, Lothar [9 ]
Hernandez, Adrian F. [2 ]
Armstrong, Paul W. [1 ]
机构
[1] Univ Alberta, Canadian VIGOUR Ctr, 4-120 Katz Grp Ctr Pharm & Hlth Res, Edmonton, AB T6G 2E1, Canada
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA
[4] Univ Arizona, Sarver Heart Ctr, Tucson, AZ USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[6] Wayne State Univ, Detroit, MI USA
[7] Inova Heart & Vasc Inst, Falls Church, VA USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Bayer AG, Wuppertal, Germany
关键词
clinical trial; heart failure; mortality; population; registries; PREDICTING SURVIVAL; RISK SCORE; BARRIERS;
D O I
10.1161/CIRCHEARTFAILURE.120.008242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Randomized controlled trials (RCTs) often target enrollment of patients with demographics and outcomes less representative of the broader population of interest. To provide context for the VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), we designed a registry of hospitalized patients with worsening heart failure to characterize their clinical profile, outcomes, and reasons for their nonparticipation in a RCT. METHODS: Fifty-one RCT sites in Canada and the United States participated. Eligible patients included those with chronic heart failure, hospitalized for heart failure, and an ejection fraction <45%; no other exclusions were applied. Sites identified patients between 2017 and 2019 during the RCT enrollment period. RCT eligibility criteria were applied, and non-mutually exclusive reasons for nonenrollment were captured. Mortality at 1 year was estimated via the Meta-Analysis Global Group in Chronic Heart Failure risk score or as observed in the RCT. RESULTS: Overall, 2056 patients were enrolled in the registry; 61% (n=1256) were ineligible for the RCT, 37% (n=766) were eligible but not enrolled, and 2% (n=34) were also enrolled in the RCT. Registry participants had a median age of 70, 33% were women, and 63% were White. The median risk score predicted a 20.9% 1-year mortality, higher than in the RCT (predicted 14.7% and observed 11.5%). Major reasons for ineligibility in the RCT included the use of nitrates (23%), systolic blood pressure <100 mm Hg (12%), and substance use (11%) with other exclusion criteria <10%. For eligible patients, reasons for nonparticipation in the RCT included lack of interest in participating (28%), poor compliance (25%), inability to complete follow-up (23%), too sick (20%), unable to provide consent (17%), and distance from site (15%). CONCLUSIONS: Patients with worsening heart failure in routine clinical practice exhibit high-risk features, and approximately one-third were eligible for an RCT but excluded. The majority of these nonparticipating patients had modifiable reasons.
引用
收藏
页数:8
相关论文
共 11 条
  • [1] Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Armstrong, Paul W.
    Pieske, Burkert
    Anstrom, Kevin J.
    Ezekowitz, Justin
    Hernandez, Adrian F.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Voors, Adriaan A.
    Jia, Gang
    McNulty, Steven E.
    Patel, Mahesh J.
    Roessig, Lothar
    Koglin, Joerg
    O'Connor, Christopher M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1883 - 1893
  • [2] Acute Heart Failure Perspectives From a Randomized Trial and a Simultaneous Registry
    Ezekowitz, Justin A.
    Hu, Jia
    Delgado, Diego
    Hernandez, Adrian F.
    Kaul, Padma
    Leader, Rolland
    Proulx, Guy
    Virani, Sean
    White, Michel
    Zieroth, Shelley
    O'Connor, Christopher
    Westerhout, Cynthia M.
    Armstrong, Paul W.
    [J]. CIRCULATION-HEART FAILURE, 2012, 5 (06) : 735 - 741
  • [3] Trends in Consent for Clinical Trials in Cardiovascular Disease
    Kerkhoff, Louis A.
    Butler, Javed
    Kelkar, Anita A.
    Shore, Supriya
    Speight, Candace D.
    Wall, Louisa K.
    Dickert, Neal W.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [4] Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients
    Krishnamoorthy, Arun
    Tonks, Robert W.
    Adams, Patricia A.
    Felker, G. Michael
    Patel, Chetan B.
    Mentz, Robert J.
    [J]. JOURNAL OF CARDIAC FAILURE, 2015, 21 (07) : 608 - 609
  • [5] Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials
    Martin, Seth S.
    Ou, Fang-Shu
    Newby, L. Kristin
    Sutton, Victoria
    Adams, Patricia
    Felker, G. Michael
    Wang, Tracy Y.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (07) : 762 - 769
  • [6] Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
    Pocock, Stuart J.
    Ariti, Cono A.
    McMurray, John J. V.
    Maggioni, Aldo
    Kober, Lars
    Squire, Iain B.
    Swedberg, Karl
    Dobson, Joanna
    Poppe, Katrina K.
    Whalley, Gillian A.
    Doughty, Rob N.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (19) : 1404 - 1413
  • [7] Barriers to participation in randomised controlled trials: A systematic review
    Ross, S
    Grant, A
    Counsell, C
    Gillespie, W
    Russell, I
    Prescott, R
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (12) : 1143 - 1156
  • [8] Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry
    Sartipy, Ulrik
    Dahlstrom, Ulf
    Edner, Magnus
    Lund, Lars H.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (02) : 173 - 179
  • [9] Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades
    Sepehrvand, Nariman
    Alemayehu, Wendimagegn
    Das, Debraj
    Gupta, Arjun K.
    Gouda, Pishoy
    Ghimire, Anukul
    Du, Amy X.
    Hatami, Sanaz
    Babadagli, Hazal E.
    Verma, Sanam
    Kashour, Zakariya
    Ezekowitz, Justin A.
    [J]. JAMA CARDIOLOGY, 2019, 4 (11) : 1122 - 1128
  • [10] Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores
    Simpson, Joanne
    Jhund, Pardeep S.
    Cardoso, Jose Silva
    Martinez, Felipe
    Mosterd, Arend
    Ramires, Felix
    Rizkala, Adel R.
    Senni, Michele
    Squire, Iain
    Gong, Jianjian
    Lefkowitz, Martin P.
    Shi, Victor C.
    Desai, Akshay S.
    Rouleau, Jean L.
    Swedberg, Karl
    Zile, Michael R.
    McMurray, John J. V.
    Packer, Milton
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (19) : 2059 - 2071